Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Telos Rx

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Telos Rx head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 18 · Grade B

Telos Rx

Visit Telos Rx Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 85 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make Telos Rx a bad call — it's best for readers who want glp-1 care and a needle-free oral or microdosed route on the same certified desk that also carries peptides, nad+ and hrt — and will trade fda-approved brand access and up-front pricing for the deepest menu at the lowest annual-lock rate. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
84
Supply Reliability
95
84
Transparency
90
79
Access Breadth
93
96
Clinical Oversight
92
85
Track Record
88
82
CoreAge RxBrief Score 94 · 85Telos Rx

Price, coverage & the tracker

CoreAge RxTelos Rx
Brief Score94/100 (A)85/100 (B)
Semaglutide$149/mo$49/mo (microdosed, annual)
Tirzepatide$349/mo$99/mo (annual)
CoverageAll 50 statesNot publicly listed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerStableprice stableStableprice stable

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

Telos Rx: Headline GLP tiers held flat this cycle, but the $49 microdosed and $99 tirzepatide rates are annual-lock prices — short-term plans run meaningfully higher, and everything outside GLP-1 stays unpriced until intake.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.